User:Renewgpl/sandbox

Renew Group Private Limited
Renew Group is an international conglomerate involved in the R&D, manufacturing and distributing multi-industrial products that include Medical Devices, Utilities systems, and smart connected devices for Water and Energy conservation. Renew Group has built a team of more than 250 professionals, selling products in over 20 countries in Asia, Europe and the United States.

History
Renew Group, the startup owned by Mr Bhargava and partner Ravinder Sajwan, will produce machines to make saltwater drinkable at a new US$120 million (S$169 million) plant in Singapore as well as massage bed-like devices aimed at enhancing blood circulation. Separately, in India, Mr Bhargava will begin in March to manufacture and distribute an electricity-generating bicycle for poor households that he plans to sell for as little as US$200.

His decision to move most inventions from his laboratory in suburban Detroit to Singapore reflects the city-state’s all-out efforts to attract global technology firms and build its own version of Silicon Valley. Mr Bhargava established Renew in 2013 and the business now has 35 employees with plans for an initial public offering in two to three years. 

Renew NCP
Renew™ ECP (External Counterpulsation) Therapy is a non-invasive and clinically proven process that enhances blood circulation. The therapy comprises of synchronized external pressure applied on the lower limbs during the diastole phase of the heart cycle. Renew™ NCP-5, the ECP device used in the therapy, is cleared by the U.S. Food and Drug Administration (FDA) and approved by the Singapore Health Sciences Authority (HSA) for treatment of chronic stable angina.

To date, over 200 peer-reviewed clinical studies have been performed and published to understand the benefits of ECP on some of the world’s top diseases such as cardiovascular disease, diabetes, stroke and hypertension.

Zensor
Zensor™ device is a 14 days continuous ECG and remote event device available on the market, cleared for use by the US FDA and CE marked it enables the transmission of comprehensive ECG data to allow you diagnose patient arrhythmias including Atrial Fibrillation. Patients with Atrial Fibrillation (AF) face an increased risk of stroke, dementia, heart failure and death. AF (or AFib) is the most common arrhythmia encountered in clinical practice with an estimated worldwide prevalence in 2010 of almost 34 million people.

Many patients affected by AF are asymptomatic or experience brief episodes that could be wrongly attributed to other conditions. Individuals with AF that are undiagnosed or go untreated may be at increased risk for stroke and overall mortality. Holter monitors that typically monitor patients for 24-48 hours run the risk of not capturing AF in a significant proportion of your presenting and high risk patients.